Recent Updates
Recently added Catalysts
MCK

SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION McKesson Corporation (the "Company," "we," or "our") is furnishing to investors supplemental historical financial information by new reportable segment for our quarte

Key Takeaway: SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION McKesson Corporation (the "Company," "we," or "our") is furnishing to investors supplemental historical financial information by new reportable segment for our quarterly results of fiscal 2020 and first quarter of fiscal 2021

Full Press Release Details

SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION
McKesson Corporation (the "Company," "we," or "our") is furnishing to investors supplemental historical financial information by new reportable segment for our quarterly results of fiscal 2020 and first quarter of fiscal 2021 as well as annual results for fiscal 2020 and 2019. We believe the presentation of our historical segment financial information by new reportable segment provides useful supplemental information to investors to better understand the impact of segment changes.
We reassessed our reportable segments following a change in our organizational structure to reflect our continued focus on delivering new and innovative solutions to respond to the evolving needs of the healthcare industry, customers, and patients. In connection with the completion of this change, our operating structure was realigned, and commencing in the second quarter of fiscal 2021, we will report our financial results in four reportable segments on a retrospective basis as follows: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions. Our equity method investment in Change Healthcare LLC, which was split-off from McKesson in the fourth quarter of 2020, will be included in Other for retrospective periods presented. The segment changes reflect how our chief operating decision maker allocates resources and assesses performance commencing in the second quarter of fiscal 2021. The segment changes did not impact the previously issued consolidated financial statements nor earnings per common share of McKesson for historical periods.
Exhibit I provides a reconciliation of the Company's previously reported GAAP segment financial results to Non-GAAP financial results supplemental to our quarterly results of fiscal 2020 and first quarter of fiscal 2021 as well as annual results for fiscal 2020 and 2019.
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION
In an effort to provide investors with additional information regarding the Company's financial results as determined by generally accepted accounting principles ("GAAP"), McKesson Corporation (the "Company" or "we") also presents the following Non-GAAP financial measures in this press release.
The following provides further details regarding the adjustments made to our GAAP financial results to arrive at our Non-GAAP financial measures as defined above:
Amortization of acquisition-related intangibles - Amortization expenses of intangible assets directly related to business combinations and the formation of joint ventures.
Transaction-related expenses and adjustments - Transaction, integration and other expenses that are directly related to business combinations, the formation of joint ventures, divestitures and other transaction-related costs including initial public offering costs. Examples include transaction closing costs, professional service fees, legal fees, severance charges, retention payments and employee relocation expenses, facility or other exit-related expenses, certain fair value adjustments including deferred revenues, contingent consideration and inventory, recoveries of acquisition-related expenses or post-closing expenses, bridge loan fees, and gains or losses on business combinations and divestitures of businesses that do not qualify as discontinued operations.
LIFO inventory-related adjustments - LIFO inventory-related non-cash expense or credit adjustments.
Gains from antitrust legal settlements - Net cash proceeds representing the Company's share of antitrust lawsuit settlements.
Restructuring, impairment, and related charges - Restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted as well as long-lived asset impairments. Such charges may include employee severance, retention bonuses, facility closure or consolidation costs, lease or contract termination costs, asset impairments, accelerated depreciation and amortization, and other related expenses. The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, integration of acquired businesses, and/or company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of our underlying business, which include normal levels of reinvestment in the business. Any credit adjustments due to subsequent changes in estimates are also excluded from adjusted results.
Other adjustments - The Company evaluates the nature and significance of transactions qualitatively and quantitatively on an individual basis and may include them in the determination of our adjusted results from time to time. While not all-inclusive, other adjustments may include: adjustments to claim and litigation reserves for estimated probable losses and settlements; other asset impairments; gains or losses from debt extinguishment; and other similar substantive and/or infrequent items as deemed appropriate.
The Company believes the presentation of Non-GAAP financial measures provides useful supplemental information to investors with regard to its operating performance, as well as assists with the comparison of its past financial performance to the Company's future financial results. Moreover, the Company believes that the presentation of Non-GAAP financial measures assists investors' ability to compare its financial results to those of other companies in the same industry. However, Non-GAAP financial measures used in the press tables may be defined and calculated differently by other companies in the same industry.
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
The Company internally uses both GAAP and Non-GAAP financial measures in connection with its own financial planning and reporting processes. Management utilizes Non-GAAP financial measures when allocating resources, deploying capital, as well as assessing business performance, and determining employee incentive compensation. Nonetheless, Non-GAAP financial measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP) SUPPLEMENTAL
FOR FISCAL QUARTERS OF 2020 AND FIRST FISCAL QUARTER OF 2021
FISCAL 2020 FISCAL 2021
Quarter Ended June 30, 2019 Quarter Ended September 30, 2019 Quarter Ended December 31, 2019 Quarter Ended March 31, 2020 Quarter Ended June 30, 2020
As reported (GAAP) Adjustments As adjusted (Non-GAAP) As reported (GAAP) Adjustments As adjusted (Non-GAAP) As reported (GAAP) Adjustments As adjusted (Non-GAAP) As reported (GAAP) Adjustments As adjusted (Non-GAAP) As reported (GAAP) Adjustments As adjusted (Non-GAAP)
REVENUES
U.S. Pharmaceutical $ 43,789 $ - $ 43,789 $ 45,613 $ - $ 45,613 $ 46,453 $ - $ 46,453 $ 45,845 $ - $ 45,845 $ 44,670 $ - $ 44,670
International 9,407 - 9,407 9,321 - 9,321 9,864 - 9,864 9,749 - 9,749 8,552 - 8,552
Medical-Surgical Solutions 1,903 - 1,903 2,056 - 2,056 2,141 - 2,141 2,205 - 2,205 1,801 - 1,801
Prescription Technology Solutions 629 - 629 626 - 626 714 - 714 736 - 736 656 - 656
Revenues $ 55,728 $ - $ 55,728 $ 57,616 $ - $ 57,616 $ 59,172 $ - $ 59,172 $ 58,535 $ - $ 58,535 $ 55,679 $ - $ 55,679
OPERATING PROFIT (LOSS)
U.S. Pharmaceutical $ 576 $ 14 $ 590 $ 641 $ (3 ) $ 638 $ 677 $ (34 ) $ 643 $ 851 $ (94 ) $ 757 $ 613 $ (23 ) $ 590
International 31 51 82 30 67 97 (290 ) 435 145 68 69 137 3 70 73
Medical-Surgical Solutions 125 34 159 129 37 166 124 60 184 121 49 170 89 35 124
Prescription Technology Solutions 100 18 118 98 17 115 82 21 103 116 16 132 68 18 86
Other (a) 4 104 108 (1,454 ) 1,493 39 (33 ) 84 51 370 (315 ) 55 - - -
Subtotal 836 221 1,057 (556 ) 1,611 1,055 560 566 1,126 1,526 (275 ) 1,251 773 100 873
Corporate expenses, net (161 ) 37 (124 ) (350 ) 218 (132 ) (202 ) 34 (168 ) (260 ) 44 (216 ) (68 ) (98 ) (166 )
Income (loss) from continuing operations before interest expense and income taxes $ 675 $ 258 $ 933 $ (906 ) $ 1,829 $ 923 $ 358 $ 600 $ 958 $ 1,266 $ (231 ) $ 1,035 $ 705 $ 2 $ 707
OPERATING PROFIT (LOSS) AS A % OF REVENUES
U.S. Pharmaceutical 1.32 % 1.35 % 1.41 % 1.40 % 1.46 % 1.38 % 1.86 % 1.65 % 1.37 % 1.32 %
International 0.33 0.87 0.32 1.04 (2.94 ) 1.47 0.70 1.41 0.04 0.85
Medical-Surgical Solutions 6.57 8.36 6.27 8.07 5.79 8.59 5.49 7.71 4.94 6.89
Prescription Technology Solutions 15.90 18.76 15.65 18.37 11.48 14.43 15.76 17.93 10.37 13.11
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP) SUPPLEMENTAL
FOR FISCAL 2020 and 2019
Year Ended March 31, 2020 Year Ended March 31, 2019
As reported (GAAP) Adjustments As adjusted (Non-GAAP) As reported (GAAP) Adjustments As adjusted (Non-GAAP)
REVENUES
U.S. Pharmaceutical $ 181,700 $ - $ 181,700 $ 166,189 $ - $ 166,189
International 38,341 - 38,341 38,023 - 38,023
Medical-Surgical Solutions 8,305 - 8,305 7,618 - 7,618
Prescription Technology Solutions 2,705 - 2,705 2,489 - 2,489
Revenues $ 231,051 $ - $ 231,051 $ 214,319 $ - $ 214,319
OPERATING PROFIT (LOSS)
U.S. Pharmaceutical $ 2,745 $ (117 ) $ 2,628 $ 2,710 $ (233 ) $ 2,477
International (161 ) 622 461 (1,903 ) 2,345 442
Medical-Surgical Solutions 499 180 679 455 150 605
Prescription Technology Solutions 396 72 468 355 74 429
Other (a) (1,113 ) 1,366 253 (104 ) 436 332
Subtotal 2,366 2,123 4,489 1,513 2,772 4,285
Corporate expenses, net (973 ) 333 (640 ) (639 ) 138 (501 )
Income from continuing operations before interest expense and income taxes $ 1,393 $ 2,456 $ 3,849 $ 874 $ 2,910 $ 3,784
OPERATING PROFIT (LOSS) AS A % OF REVENUES
U.S. Pharmaceutical 1.51 % 1.45 % 1.63 % 1.49 %
International (0.42 ) 1.20 (5.00 ) 1.16
Medical-Surgical Solutions 6.01 8.18 5.97 7.94
Prescription Technology Solutions 14.64 17.30 14.26 17.24
Last updated: Sep 22, 2020